Library / Cagrilintide
Some human studies
Cagrilintide
Long-acting amylin analogue · Weight & GLP-1 · AM833; part of CagriSema
What it is
A long-acting version of amylin, a hormone released with insulin that helps you feel full. It works differently from GLP-1 medicines, so it is being studied alongside them.
What research covers
In the REDEFINE 1 trial, cagrilintide combined with semaglutide (CagriSema) led to about 20% average weight loss over 68 weeks, compared with about 12% for cagrilintide alone. It is still investigational at the time of writing.
Reported side effects
- Nausea, vomiting and other stomach upsets
- Injection-site reactions
- Fatigue
Not suitable for, or talk to a doctor first
- Pregnancy
- History of pancreatitis
Legal status
| Australia | Not an approved medicine in Australia. Peptides like this are generally prescription-only (Schedule 4) and need a prescription to import. Check current rules with the TGA. |
|---|---|
| United States | Investigational. Not FDA-approved. |
| Sport | Athletes should check the current WADA prohibited list, which changes every year. |
Rules change. Check with the TGA (Australia), your local regulator, or WADA for sport.
Key references
- Garvey et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). NEJM, 2025.
General information, not advice. Talk to a qualified healthcare professional before starting, changing or stopping anything.